한글목차

FLUBLOK QUADRIVALENT는 18세 이상 성인을 대상으로 하는 4가 독감 백신으로, FDA의 승인을 받은 유일한 재조합 단백질 기반 독감 백신입니다. 향후 몇년안에 세계로 확대될 예정입니다.

플루존 고용량 4가 백신은 특히 65세 이상 고령자의 독감 예방 효과를 높이기 위해 고안된 백신으로 2019년 11월 FDA의 승인을 받았습니다. 현재 FLUZONE High-dose TRIVALENT를 완전히 대체하고 있으며, 2가지 인플루엔자 A주와 2가지 인플루엔자 B주를 60μg/주 함유하고 있습니다.

FLUZONE: QIV HD는 미국과 유럽에서 허가된 고용량 4가 독감백신으로, 면역체계의 노화(면역노화)로 인해 표준용량의 독감백신에 반응하지 않는 고령층을 대상으로 합니다. 회사 측에 따르면 이번 3상 시험은 등록 시험이며, 소아 집단에서 안전성과 유효성을 평가하기 위한 3상 시험이 진행 중이라고 밝혔습니다.

앞으로 수년간 계절성 독감 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 도전과제를 평가하고, FLUBLOK QUADRIVALENT의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 계절성 독감에 대한 다른 신흥 제품들이 FLUBLOK QUADRIVALENT와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신약의 출시가 시장에 큰 영향을 미칠 것으로 예상됩니다.

주요 6개국의 FLUBLOK QUADRIVALENT 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 계절성 인플루엔자에 대한 FLUBLOK QUADRIVALENT의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 FLUBLOK QUADRIVALENT 시장 평가

• 계절성 인플루엔자에 대한 FLUBLOK QUADRIVALENT의 시장 전망
• 주요 6개국 시장 분석
  • 주요 6개국의 계절성 인플루엔자에 대한 FLUBLOK QUADRIVALENT의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"FLUBLOK QUADRIVALENT Drug Insight and Market Forecast - 2032" report provides comprehensive insights about FLUBLOK QUADRIVALENT for seasonal influenza in the six major markets. A detailed picture of the FLUBLOK QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the FLUBLOK QUADRIVALENT for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FLUBLOK QUADRIVALENT market forecast analysis for seasonal influenza in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

FLUBLOK is a quadrivalent influenza vaccine for adults aged 18 and older. It is the only recombinant protein-based influenza vaccine approved by the FDA. FLUBLOK is currently sold in the US, the United Kingdom, Hong Kong, and Taiwan, with continued global expansion planned over the next several years.

FLUZONE High-dose Quadrivalent, designed specifically to provide greater protection against influenza for people aged 65 and older, was approved by the FDA in November 2019. It has now fully replaced FLUZONE High-dose TRIVALENT and contains two Influenza A and two Influenza B strains at 60 µg/strain.

FLUZONE: QIV HD is a higher dose quadrivalent influenza vaccine licensed in the US and Europe for the elderly population, who do not respond as well to standard-dose influenza vaccines due to aging of the immune system (immuno-senescence). A Phase III trial is ongoing to evaluate safety and efficacy in the pediatric population, and according to the company, this Phase III trial is a registrational trial.

Dosage and administration

A sterile solution for injection is supplied in 0.5 mL single-dose prefilled syringes.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the FLUBLOK QUADRIVALENT description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on FLUBLOK QUADRIVALENT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FLUBLOK QUADRIVALENT research and development activities in seasonal influenza across the United States and Europe.
• The report also covers the patents information with expiry timeline around FLUBLOK QUADRIVALENT.
• The report contains forecasted sales of FLUBLOK QUADRIVALENT for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for FLUBLOK QUADRIVALENT in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FLUBLOK QUADRIVALENT Analytical Perspective by DelveInsight

In-depth FLUBLOK QUADRIVALENT Market Assessment

This report provides a detailed market assessment of FLUBLOK QUADRIVALENT for seasonal influenza in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

FLUBLOK QUADRIVALENT Clinical Assessment

The report provides the clinical trials information of FLUBLOK QUADRIVALENT for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FLUBLOK QUADRIVALENT dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to FLUBLOK QUADRIVALENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FLUBLOK QUADRIVALENT in seasonal influenza.
• Our in-depth analysis of the forecasted sales data of FLUBLOK QUADRIVALENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FLUBLOK QUADRIVALENT in seasonal influenza.

Key Questions:

• What is the product type, route of administration and mechanism of action of FLUBLOK QUADRIVALENT?
• What is the clinical trial status of the study related to FLUBLOK QUADRIVALENT in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FLUBLOK QUADRIVALENT development?
• What are the key designations that have been granted to FLUBLOK QUADRIVALENT for seasonal influenza?
• What is the forecasted market scenario of FLUBLOK QUADRIVALENT for seasonal influenza?
• What are the forecasted sales of FLUBLOK QUADRIVALENT in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to FLUBLOK QUADRIVALENT for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. FLUBLOK QUADRIVALENT Overview in seasonal influenza

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. FLUBLOK QUADRIVALENT Market Assessment

• 5.1. Market Outlook of FLUBLOK QUADRIVALENT in seasonal influenza
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of FLUBLOK QUADRIVALENT in the 6MM for seasonal influenza
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of FLUBLOK QUADRIVALENT in the United States for seasonal influenza
  • 5.3.2. Market Size of FLUBLOK QUADRIVALENT in Germany for seasonal influenza
  • 5.3.3. Market Size of FLUBLOK QUADRIVALENT in France for seasonal influenza
  • 5.3.4. Market Size of FLUBLOK QUADRIVALENT in Italy for seasonal influenza
  • 5.3.5. Market Size of FLUBLOK QUADRIVALENT in Spain for seasonal influenza
  • 5.3.6. Market Size of FLUBLOK QUADRIVALENT in the United Kingdom for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options